DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Monday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $0.67 on Monday. The firm has a market capitalization of $129.22 million, a P/E ratio of -1.72 and a beta of 0.73. DBV Technologies has a one year low of $0.65 and a one year high of $2.37. The company’s fifty day moving average is $0.75 and its two-hundred day moving average is $0.84.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, March 7th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.10. The company had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period in the previous year, the firm earned ($0.23) EPS. On average, sell-side analysts forecast that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cowen AND Company LLC acquired a new position in shares of DBV Technologies during the 4th quarter worth $49,000. Landscape Capital Management L.L.C. acquired a new position in shares of DBV Technologies during the 3rd quarter worth $94,000. Finally, Optiver Holding B.V. raised its stake in shares of DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares during the last quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.